Novartis (NVS), a global pharmaceutical giant, is showing strong technical signals that suggest it may be on the cusp of a significant bullish reversal, according to market analyst Frank Cappelleri. Following a recent earnings report, the stock has maintained its upward momentum, hovering near recent highs and testing the neckline of a large inverse head-and-shoulders pattern. A decisive break above this resistance level could trigger an upside target of approximately $176, marking a notable completion of a bullish pattern after a prolonged period of consolidation.
The technical indicators supporting this optimistic outlook are compelling. On a weekly chart, NVS has consistently held above its rising 40-week moving average since the spring of 2025, a trend also supported by the 14-week Relative Strength Index (RSI) remaining above the crucial 50-point midpoint. This suggests a robust long-term uptrend.
Historically, periods where NVS maintained this bullish combination—holding above the rising 40-week moving average with the RSI oscillating between 50 and overbought territory—have preceded significant advances. For instance, a similar pattern between late 2012 and mid-2015 fueled an approximately 80% rally.
Cappelleri emphasizes the importance of monitoring key indicators for trend continuation. The breakout above resistance levels would not only signal a short-term upside but also reinforce the stock's well-defined long-term uptrend, both on an absolute basis and relative to its pharmaceutical peers.
While NVS trades largely outside the most common U.S. ETFs, its significant weighting in healthcare-focused funds, such as the VanEck Pharmaceutical ETF (PPH), highlights its importance in the sector. The stock has recently outperformed PPH, and further strengthening of this relative performance is anticipated if the long-term uptrend persists.
The risk-reward setup is also favorable, with a suggested stop-loss near $151, close to the base of the pattern's right shoulder, providing a sound strategy for investors looking to capitalize on this potential breakout.
